makes Johns Hopkins Urology consistently — for 16 years in
a row — ranked the very "Best of The Best" by a national news
magazine? It's discovery, the subject of this newsletter, and the
heart of the Brady Urological Institute. It's what drives everyone
who works here. We're making a difference, and we know it —
and we want to keep on making life better for our patients and their
families. Our unparalleled scientific discoveries have forever changed
the way prostate cancer is diagnosed and treated worldwide.
The discoveries written about on these pages show
that there is something truly fascinating, even revolutionary going
on at the Brady Urological Institute. We specialize in translating
scientific discoveries into practical applications. This "translational
research" typically begins at "the bench" with basic research, in
which scientists study disease at a molecular or cellular level,
then progresses to the clinical level — the patient's "bedside."
Translational research, when pursued with vigor,
has a profound impact on improving our ability to care for our patients.
Led by Alan Partin, Director of Urology, in the great tradition
started by Patrick Walsh, we are working to expedite this "bench-to-bedside"
process. Now more than ever, our vision is one of collaborative
scientific interactions, hastening promising observations and facilitating
scientific discoveries. The primary goal of all our research and
clinical efforts is meeting our patients' needs. For example:
- Patients need flexible and diverse, custommade treatment plans.
Just as prostate cancer is different in every man, treatment must
be, as well. Every man with prostate cancer who comes to Johns
Hopkins will find physicians seeking the most appropriate treatment
option for him. "Onesize- fits-all" care is not an option here.
- Patients need multi-disciplinary clinical trials and the latest
breakthroughs — discoveries that can change their lives — as quickly
as possible. Our scientists understand that some patients do not
have the luxury of time.
- Patients need better and more accurate tests to diagnose disease
as early as possible. Currently, PSA is the best tool we have
for prostate cancer diagnosis; our scientists are working to change
this. We are intensively studying biomarkers that will not miss
cancer or subject men to unnecessary biopsies.
- Patients need better treatment options. That's why Hopkins
scientists are leading discoveries in new technologies and treatment
for prostate cancer.
The greatest challenge we face in bringing the latest research
from the laboratory to our patients is finding the resources necessary
to support the process. With increased competition for Federal funding
and ongoing cuts in these critical funds, we need your support now
more than ever. With your help, we can continue our battle to conquer
prostate cancer. We hope you will make a gift to support The Brady
Urological Institute, using the enclosed envelope. For question
about making a gift, or if you are considering a gift of stock,
real estate, IRA, or other asset, please call